Meeting
2021 ASCO Annual Meeting
Circulating tumor DNA as a noninvasive marker of resectability in ovarian carcinomas.
Authors
Roxane Mari
Department of Medical Oncology, Institut Paoli Calmettes, Marseille, France
Roxane Mari , Christophe Pomel , Pierre-Emmanuel Colombo , Fabrice Narducci , Séverine Garnier , Nadine Carbuccia , Arnaud Guille , Magali Provansal , Maria-Antonietta Cappiello , Fréderique Rousseau , Guillaume Blache , Eric Lambaudie , Daniel Birnbaum , Francois Bertucci , Renaud Sabatier
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Clinical Trial Registration Number
NCT03302884
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 5548)
DOI
10.1200/JCO.2021.39.15_suppl.5548
Abstract #
5548
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Novel potential mechanisms of acquired resistance to anti-EGFR monoclonal antibody (mAb) therapy detected in liquid biopsies (LBx) from patients (pts) with advanced colorectal cancer (CRC).
First Author: Christine Megerdichian Parseghian
Poster
2023 ASCO Annual Meeting
Trends in the use of neoadjuvant chemotherapy for low-grade serous ovarian cancer in the United States.
First Author: Jason Silberman
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Feasibility of circulating tumor DNA (ctDNA) to guide organ preservation in patients with node-negative rectal cancer undergoing neoadjuvant chemotherapy, excision, and observation in the phase II CCTG CO.28 trial.
First Author: Jonathan M. Loree
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Utility of circulating tumor DNA (ctDNA) in the management of appendiceal adenocarcinoma (AA).
First Author: Mohammad A. Zeineddine